Total Payments
$18,400
2024 Payments
$1,125
Companies
4
Transactions
18
Medicare Patients
1,534
Medicare Billing
$164,907
Payment Breakdown by Category
Consulting$15,175 (82.5%)
Research$3,200 (17.4%)
Education$24.90 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,175 | 15 | 82.5% |
| Unspecified | $3,200 | 2 | 17.4% |
| Education | $24.90 | 1 | 0.1% |
Payments by Type
General
$15,200
16 transactions
Research
$3,200
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $11,800 | 13 | $0 (2020) |
| Instylla, Inc. | $3,375 | 2 | $0 (2024) |
| Novo Nordisk AS | $3,200 | 2 | $0 (2022) |
| INTERCEPT PHARMACEUTICALS, INC. | $24.90 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,125 | 1 | Instylla, Inc. ($1,125) |
| 2023 | $2,250 | 1 | Instylla, Inc. ($2,250) |
| 2022 | $2,825 | 2 | Novo Nordisk AS ($2,800) |
| 2021 | $400.00 | 1 | Novo Nordisk AS ($400.00) |
| 2020 | $2,000 | 2 | Merck Sharp & Dohme Corporation ($2,000) |
| 2019 | $4,000 | 4 | Merck Sharp & Dohme Corporation ($4,000) |
| 2018 | $4,000 | 4 | Merck Sharp & Dohme Corporation ($4,000) |
| 2017 | $1,800 | 3 | Merck Sharp & Dohme Corporation ($1,800) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/19/2024 | Instylla, Inc. | INSTYLLA DELIVERY KIT (Device), INSTYLLA MICROCATHETER | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Liquid Embolics for Interventional Radiology | ||||||
| 05/17/2023 | Instylla, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 07/29/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Education | In-kind items and services | $24.90 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 03/22/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: NN9535-4386 • Category: Diabetes | ||||||
| 02/11/2021 | Novo Nordisk AS | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: NN9535-4386 • Category: Diabetes | ||||||
| 02/21/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/31/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2019 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/28/2019 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/05/2019 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/28/2019 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/15/2018 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/24/2018 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/23/2018 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/24/2018 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/26/2017 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/24/2017 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $50.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9535-4386 | Novo Nordisk AS | $3,200 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 387 | 491 | $261,367 | $42,767 |
| 2022 | 10 | 383 | 431 | $265,097 | $39,280 |
| 2021 | 12 | 398 | 504 | $312,535 | $48,653 |
| 2020 | 11 | 366 | 422 | $275,522 | $34,207 |
Total Patients
1,534
Total Services
1,848
Medicare Billing
$164,907
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 130 | 163 | $71,301 | $12,536 | 17.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 37 | 37 | $51,726 | $8,153 | 15.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 42 | 47 | $29,971 | $5,234 | 17.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 74 | $22,300 | $4,957 | 22.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 32 | $14,527 | $3,224 | 22.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 16 | 16 | $19,920 | $3,113 | 15.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $9,846 | $1,982 | 20.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $19,695 | $1,421 | 7.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 12 | 15 | $6,051 | $1,048 | 17.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $12,111 | $805.86 | 6.7% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 63 | 63 | $3,919 | $292.56 | 7.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 49 | 49 | $65,544 | $10,807 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 93 | 108 | $45,073 | $9,100 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 36 | $19,080 | $3,345 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 24 | $14,599 | $3,004 | 20.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 15 | 15 | $18,675 | $2,994 | 16.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 45 | $12,749 | $2,739 | 21.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 24 | 24 | $31,512 | $1,995 | 6.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $8,118 | $1,728 | 21.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $6,420 | $1,389 | 21.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $14,707 | $1,066 | 7.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 23 | 23 | $24,167 | $782.83 | 3.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 73 | 73 | $4,453 | $329.41 | 7.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 123 | $58,573 | $12,920 | 22.1% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 44 | 44 | $60,674 | $9,689 | 16.0% |
About Dr. Karin Andersson, MD
Dr. Karin Andersson, MD is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972585511.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Karin Andersson, MD has received a total of $18,400 in payments from pharmaceutical and medical device companies, with $1,125 received in 2024. These payments were reported across 18 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($15,175).
As a Medicare-enrolled provider, Andersson has provided services to 1,534 Medicare beneficiaries, totaling 1,848 services with total Medicare billing of $164,907. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location Boston, MA
- Active Since 11/18/2005
- Last Updated 10/23/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1972585511
Products in Payments
- STEGLATRO (Drug) $11,800
- INSTYLLA DELIVERY KIT (Device) $1,125
- OCALIVA (Drug) $24.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
Internal Medicine $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Internal Medicine $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Internal Medicine $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M